Congress moves to strip PBMs of hidden drug markups, mandate pharmacy access

What it does

This bill restricts pharmacy benefit managers (PBMs) from taking profits beyond flat-fee compensation for services, requires them to disclose detailed drug pricing and rebate data to Medicare plans, mandates that any willing pharmacy can join Medicare drug plan networks, and establishes enforcement mechanisms including civil penalties for violations. It also requires the Secretary of Health and Human Services to publish reports on pharmacy access and PBM compensation structures, and extends similar transparency and accountability rules to PBMs serving employer health plans.

Why we flagged it

The bill's core mechanism is a structural prohibition on PBM profit-taking beyond flat fees, paired with mandatory disclosure of pricing, rebates, and compensation data. This is regulatory reform targeting market opacity and conflicts of interest in drug distribution, not a subsidy, carve-out, or commemorative measure.

What the text implies

• PBMs may respond by raising flat-fee amounts to compensate for lost rebate revenue, potentially shifting costs from hidden markups to transparent but higher service charges—benefiting transparency but not necessarily lowering total plan costs.
• The 'any willing pharmacy' requirement may strain network quality controls and increase administrative burden on plans, though it expands beneficiary choice and may reduce PBM steering toward affiliated pharmacies.

The full analysis lists 5 implications of this text.

Who stands to gain

Medicare beneficiaries (lower out-of-pocket costs, expanded pharmacy access); Employer plan members (transparency, reduced hidden markups); Independent and retail pharmacies (access to networks, reduced steering to PBM affiliates)